ScholarLens Back to search
2002•Western Journal of MedicineOpen access

Thrombolysis for acute ischemic stroke: still a treatment for the few by the few

Joanna M. Wardlaw

Open full text 28 citations

Abstract

The National Institute of Neurological Disorders and Stroke (NINDS) trialwas groundbreaking.1It demonstrated that stroke patients could be admitted to hospital, scanned,and treated within 3 hours of stroke, a major achievement in the early 1990s.The Food and Drug Administration accepted the NINDS evidence (actuallyconducted as 2 consecutive trials, only 1 of which gave positive results) andlicensed recombinant tissue plasminogen activator (tPA) for the treatment ofstroke.

Open-access reader

About this research paper

What this paper is about

The National Institute of Neurological Disorders and Stroke (NINDS) trialwas groundbreaking.1It demonstrated that stroke patients could be admitted to hospital, scanned,and treated within 3 hours of stroke, a major achievement in the early 1990s.The Food and Drug Administration accepted the NINDS evidence (actuallyconducted as 2 consecutive trials, only 1 of which gave positive results) andlicensed recombinant tissue plasminogen activator (tPA) for the treatment ofstroke.

Why it matters

OpenAlex reports 28 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The National Institute of Neurological Disorders and Stroke (NINDS) trialwas groundbreaking.1It demonstrated that stroke patients could be admitted to hospital, scanned,and treated within 3 hours of stroke, a major achievement in the early 1990s.The Food and Drug Administration accepted the NINDS evidence (actuallyconducted as 2 consecutive trials, only 1 of which gave positive results) andlicensed recombinant tissue plasminogen activator (tPA) for the treatment ofstroke.

Key concepts: Thrombolysis, Medicine, Ischemic stroke, Cardiology, Stroke (engine), Acute stroke, Internal medicine, Ischemia

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Thrombolysis for acute ischemic stroke: still a treatment for the few by the few — Research Paper | ScholarLens